CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carci
Go back to CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carci| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 54.70 +0.70 (1.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.00 | 52 Week High | $77.12 | |||
| Open | $54.20 | 52 Week Low | $49.03 | |||
| Day High | $54.73 | P/E | 35.52 | |||
| Day Low | $54.00 | EPS | $1.54 | |||
| Volume | 16,238,704 | |||||
